Lead Product(s): OMNI nuclease
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Deal Size: $61.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 15, 2020
The funding will accelerate novel OMNI gene editing platform into a broad therapeutic product pipeline.